Rapt Therapeutics Unveils Pipeline Progress for Ozureprubart in Allergic Diseases
Rapt Therapeutics Inc. has updated its clinical development programs for inflammatory diseases, focusing on Ozureprubart (RPT904), a next-generation anti-IgE antibody for food allergies and chronic spontaneous urticaria (CSU). The drug aims for less frequent dosing to enhance patient compliance. Positive Phase 2 data in CSU show 16-week durability. A Phase 2b trial for food allergy is underway, with results expected in early 2027. Rapt holds ex-China rights, while Jemincare has rights in China and nearby regions. The company is also advancing its oncology and inflammatory disease pipeline.
Rapt Therapeutics Inc. has provided an update on its clinical development programs targeting inflammatory diseases. The company highlighted Ozureprubart (RPT904), a next-generation anti-IgE antibody intended for the treatment of food allergies and chronic spontaneous urticaria (CSU). Ozureprubart is designed for less frequent dosing and aims to improve patient compliance compared to existing therapies. Positive Phase 2 data in CSU have been reported, demonstrating 16-week durability. Rapt has initiated a Phase 2b trial in food allergy, with data expected in the first half of 2027, and plans to discuss the Phase 3 development path for CSU with regulatory agencies. The company noted that it holds ex-China rights to Ozureprubart, while Jemincare has rights in China, Taiwan, Hong Kong, and Macau. Rapt also continues to advance its pipeline in oncology and other inflammatory diseases. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapt Therapeutics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
